Expert Insights for the Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

EP: 1.An Expert Insights on Recent Advancements in LS-SCLC

EP: 2.The Key Updates in the Treatment of ES-SCLC

EP: 3.An Expert Perspectives on Tarlatamab in ES-SCLC

EP: 4.Looking Ahead With SCLC: ADCs and Other Novel Agents

EP: 5.The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

EP: 6.Personalizing Adjuvant Targeted Therapies in Early-Stage NSCLC

EP: 7.The New Targeted Approaches in Unresectable Early-Stage NSCL

EP: 8.Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

Now Viewing

EP: 9.Expert Insights for the Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

EP: 10.Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations

EP: 11.The Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

EP: 12.Tailoring Immunotherapy Strategies for the Advanced NSCLC

Video content above is prompted by the following:

• Briefly comment on MARIPOSA-2 (Popat S, et al. ESMO 2024. Abs LBA54)andthe recentFDA approval (September 2024) of combination amivantamab plus chemo as a second-line treatment option.
• How are you integrating the MARIPOSA-2 regimen into your clinical practice, and how do you sequence it with other available therapies?
• If you use MARIPOSA up front, what is your strategy in the second-line setting?
• How do emerging data from the HERTHENA-Lung01 study (Johnson M, et al. ESMO 2023. Abs 1319MO) inform your approach to managing treatment resistance management and CNS metastases?
• How might the recent CRL for HER3-DXd impact clinical practice over the next year?
• What are your perceptions of the latest data from TROPION-Lung05 and the recent shift in BLA status for Dato-DXd?(Lisberg A, et al. ASCO 2024. Abs 8593)